Workflow
HL CORP(002105)
icon
Search documents
信隆健康(002105) - 2022年09月28日投资者关系活动记录表
2022-11-11 02:08
证券代码:002105 证券简称:信隆健康 深圳信隆健康产业发展股份有限公司 投资者关系活动记录表 编号:2022-010 | --- | --- | --- | --- | |-------------------------|-------------------|----------------------------|------------------------------------------------------------| | | | | | | | | | | | | ■ 特定对象调研 | □ 分析师会议 | | | | □ 媒体采访 | □ 业绩说明会 | | | 投资者关系活动 类别 | □ 新闻发布会 | □ 路演活动 | | | | □ 现场参观 | | | | | □ 其它 | (请文字说明其它活动内容) | | | 参与单位名称及 人员姓名 | 招商证券 赵中平 | | | | 时间 2022 | 年 09 月 28 | 14:30--14:30 | | | | 地点 公司会议室 | | | | 上市公司接待人 员姓名 | 陈丽秋 | | | | | 1. 何? | | ...
信隆健康(002105) - 2022 Q3 - 季度财报
2022-10-26 16:00
Financial Performance - The company's revenue for Q3 2022 was ¥415,025,715.79, a decrease of 35.37% compared to the same period last year[4] - Net profit attributable to shareholders was ¥62,870,572.40, down 18.99% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥54,832,112.51, a decline of 26.43% compared to the previous year[4] - The company experienced a 23.13% decline in total revenue for the first nine months of 2022, totaling ¥1,470,016,977.28[9] - Total operating revenue for the current period is ¥1,470,016,977.28, a decrease of 23.1% compared to ¥1,912,457,854.82 in the previous period[17] - Net profit for the current period is ¥205,890,796.80, a decline of 8.7% from ¥225,561,947.18 in the previous period[18] - Basic earnings per share for the current period is 0.516, compared to 0.556 in the previous period, reflecting a decrease of 7.2%[19] Assets and Liabilities - The total assets at the end of Q3 2022 were ¥1,970,861,326.33, a decrease of 13.65% from the end of the previous year[4] - The company’s total liabilities decreased by 13.65% compared to the end of the previous year[4] - Total current assets as of September 30, 2022, amount to ¥1,325,392,627.57, a decrease from ¥1,641,686,202.93 at the beginning of the year[15] - Total liabilities decreased to ¥907,363,060.64 from ¥1,338,888,575.65[16] - Long-term borrowings decreased to ¥58,438,531.82 from ¥88,998,534.44[16] Cash Flow - The cash flow from operating activities for the year-to-date was ¥206,448,259.93, an increase of 87.41% compared to the same period last year[4] - Cash flow from operating activities for the current period is ¥206,448,259.93, an increase of 87.0% from ¥110,158,422.51 in the previous period[20] - Cash flow from investing activities shows a net outflow of ¥40,723,436.96, improving from a net outflow of ¥87,598,323.25 in the previous period[21] - Cash flow from financing activities results in a net outflow of ¥200,604,289.29, compared to a smaller net outflow of ¥6,005,841.26 in the previous period[21] - The ending cash and cash equivalents balance is ¥431,808,546.64, down from ¥459,199,753.69 at the beginning of the period[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 20,865[11] - The largest shareholder, Litian Development Co., Ltd., holds 41.93% of shares, totaling 154,522,500 shares[11] - The company has no preferred shareholders among the top ten shareholders[12] Other Financial Metrics - Research and development expenses for the year-to-date were ¥43,969,187.88, a decrease of 21.67% compared to the previous year[9] - Cash and cash equivalents decreased to ¥431,808,546.64 from ¥459,199,753.69[14] - Accounts receivable decreased significantly to ¥456,237,670.13 from ¥636,496,632.73[14] - Inventory decreased to ¥320,770,164.60 from ¥435,013,849.64[15] - Total equity increased to ¥1,063,498,265.69 from ¥943,627,818.06[16] - Other comprehensive income after tax for the current period is ¥8,713,647.26, significantly higher than ¥1,227,921.29 in the previous period[18] - The company has not undergone an audit for the third quarter report[22]
信隆健康(002105) - 2022 Q2 - 季度财报
2022-08-25 16:00
Financial Performance - The company's operating revenue for the first half of 2022 was CNY 1,054,991,261.49, a decrease of 16.95% compared to CNY 1,270,263,768.02 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was CNY 125,132,833.08, showing a slight increase of 0.02% from CNY 125,102,234.06 year-on-year[20]. - The net cash flow from operating activities significantly improved to CNY 79,198,248.76, an increase of 538.90% compared to CNY 12,396,038.70 in the previous year[20]. - Total assets at the end of the reporting period were CNY 2,140,167,781.61, down 6.24% from CNY 2,282,516,393.71 at the end of the previous year[20]. - The net assets attributable to shareholders increased by 4.21% to CNY 888,897,855.86 from CNY 852,946,415.37 at the end of the previous year[20]. - The basic and diluted earnings per share remained unchanged at CNY 0.343[20]. - The weighted average return on equity decreased to 13.67%, down 3.50% from 17.17% in the previous year[20]. - The company reported non-recurring gains and losses totaling CNY 10,529,587.79 for the period[24]. - The company's total revenue for the first half of 2022 was CNY 1,054.99 million, a decrease of 16.95% year-on-year, with foreign revenue increasing by 17.41% to CNY 710.14 million, while domestic revenue fell by 48.18% to CNY 344.85 million[59]. - The company's net profit attributable to shareholders was CNY 125.13 million, remaining stable with a slight increase of 0.02% compared to the previous year, primarily due to a significant increase in exchange gains from the depreciation of the RMB against the USD[59]. - The company's cash flow from operating activities showed a substantial increase of 538.90%, reaching CNY 79.20 million, attributed to improved sales collections[60]. Market Trends and Demand - The European market is projected to see electric bicycle demand exceed 5 million units in 2022, with a significant shift towards electric assist bicycles and cargo bicycles due to changing consumer preferences[38]. - The company anticipates that the demand for electric assist bicycles in the EU will continue to grow, with a forecast of over 6.5 million units sold by 2025[34]. - The domestic market is experiencing increased demand for shared bicycles and mid-to-high-end sports bicycles, driven by post-pandemic personal travel trends[40]. - By 2030, Europe is expected to sell 30 million bicycles annually, a 47% increase from 2019, with e-bike sales projected to grow from 3 million units in 2019 to 17 million units[41]. - The global bicycle market is forecasted to expand by 37.5% from 2019 to 2024, with revenues reaching $62 billion, and the e-bike market value expected to hit $24.4 billion by 2024[41]. - The global electric scooter market is projected to reach a production volume of 10.01 million units and a market value of $3.341 billion by 2027, with a compound annual growth rate of approximately 14.99% from 2021 to 2027[44]. - The global smart electric scooter market could reach $50 billion by 2025, with North America accounting for $15 billion and China for $8 billion[45]. - The electric wheelchair market in China is experiencing steady growth, driven by an increasing demand from the aging population, which includes 264 million individuals aged 60 and above, representing 18.7% of the total population[54]. Company Strategy and Operations - The company has established production bases in South China and North China, and has set up a facility in Vietnam to mitigate the impacts of the US-China trade war and stringent anti-dumping policies in Europe[28]. - The company is focusing on cross-industry collaborations and product development to adapt to the evolving market landscape and consumer preferences[40]. - The company has successfully developed a series of wheelchairs in collaboration with top global companies, enhancing its competitive edge in the rehabilitation equipment sector[31]. - The company’s automated welding technology in the sports equipment sector has achieved over 98% automation, allowing for large-scale order production[30]. - The company plans to expand its market presence through new product launches and strategic partnerships in the upcoming quarters[158]. - The company aims to enhance its market expansion strategies, particularly in the health industry, to drive future revenue growth[162]. - The company is actively investing in new product development and technological advancements to stay competitive in the market[162]. Financial Position and Investments - Cash and cash equivalents at the end of the reporting period were CNY 409,856,172.72, a decrease of 0.97% from CNY 459,199,753.69 at the end of the previous year[68]. - Short-term borrowings increased by 3.56% to CNY 512,336,390.73, compared to CNY 465,192,826.93 at the end of the previous year[68]. - The company reported an investment loss of CNY 2,353,981.12, primarily due to losses from its associate Tian Teng Power[66]. - Total investment during the reporting period was CNY 43,006,250.78, an increase of 8.53% compared to CNY 39,627,691.30 in the same period last year[72]. - The company recognized a performance compensation income of CNY 17,630,400.20 from its associate Tian Teng Power due to unmet performance commitments[70]. - The company's asset-liability ratio stood at 53.58% at the end of the reporting period, indicating potential financial risk[80]. - The main raw materials include steel pipes, aluminum pipes, and aluminum ingots, with cost control measures in place to mitigate price fluctuations[80]. Environmental and Social Responsibility - No significant environmental pollution issues were reported, and all pollution control facilities are operating normally[89]. - The company has established an emergency response plan for environmental incidents, which was approved in December 2018[91]. - The company is committed to fulfilling its social responsibilities and supporting public welfare initiatives in the future[96]. - The company has not engaged in any significant asset or equity sales during the reporting period[76][77]. - The company has not reported any changes in the scope of consolidation compared to the previous year, ensuring stability in its operations[171]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 20,773[127]. - The largest shareholder, LITIAN DEVELOPMENT CO., LTD., holds 41.93% of the shares, totaling 154,522,500 shares[127]. - FERNANDO CORPORATION is the second-largest shareholder with a 5.68% stake, amounting to 20,926,447 shares[127]. - The report indicates that there are no shareholders with pledged, marked, or frozen shares among the top 10 shareholders[127]. - The company has not conducted any repurchase transactions during the reporting period[128]. Compliance and Governance - The company has a well-structured governance framework, including a board of directors and various specialized committees[169]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring that financial statements accurately reflect its financial position, operating results, and cash flows[175]. - The company confirms that there are no significant doubts regarding its ability to continue as a going concern for the next 12 months[173]. - The financial report for the first half of 2022 was not audited[138].
信隆健康(002105) - 2022 Q1 - 季度财报
2022-04-28 16:00
Financial Performance - The company's revenue for Q1 2022 was ¥511,351,040.77, a decrease of 12.67% compared to ¥585,539,472.88 in the same period last year[3] - Net profit attributable to shareholders was ¥45,395,423.02, down 23.57% from ¥59,397,700.22 year-on-year[3] - Total operating revenue for Q1 2022 was RMB 511,351,040.77, a decrease of 12.6% compared to RMB 585,539,472.88 in the same period last year[15] - Operating profit for Q1 2022 was RMB 57,840,592.69, compared to RMB 70,429,974.32 in Q1 2021, reflecting a decline of 18.0%[16] - The total comprehensive income attributable to the parent company was CNY 45.47 million, compared to CNY 59.43 million in Q1 2021, reflecting a decrease of 23.5%[20] - The net profit for Q1 2022 was CNY 51.93 million, down 20.38% from CNY 65.25 million in Q1 2021[20] Cash Flow and Liquidity - The net cash flow from operating activities improved significantly to ¥15,248,893.03, compared to a negative cash flow of ¥15,971,124.05 in the previous year, marking a 195.48% increase[3] - The net cash flow from operating activities was CNY 15.25 million, a significant improvement from a net outflow of CNY 15.97 million in the same period last year[21] - Cash and cash equivalents at the end of Q1 2022 were RMB 458,910,565.65, slightly down from RMB 459,199,753.69 at the beginning of the year[12] - The cash and cash equivalents at the end of Q1 2022 were CNY 458.91 million, slightly down from CNY 459.20 million at the beginning of the quarter[21] - The cash outflow from investing activities was CNY 15.73 million, a decrease from CNY 17.64 million in Q1 2021[21] - The cash flow from financing activities showed a net inflow of CNY 35.19 thousand, compared to a net outflow of CNY 18.86 million in Q1 2021[21] Assets and Liabilities - Total assets decreased by 5.67% to ¥2,153,063,155.26 from ¥2,282,496,355.80 at the end of the previous year[3] - The company's total assets as of March 31, 2022, were RMB 2,153,063,155.26, down from RMB 2,282,496,355.80 at the beginning of the year, a decrease of 5.6%[15] - Total liabilities decreased to RMB 1,157,427,705.21 from RMB 1,338,849,640.65, representing a reduction of 13.5%[14] Shareholder Equity and Earnings - The company's equity attributable to shareholders increased by 5.33% to ¥898,415,685.89 from ¥852,965,312.46 at the end of the previous year[3] - The company's equity attributable to shareholders increased to RMB 898,415,685.89 from RMB 852,965,312.46, an increase of 5.3%[15] - The basic earnings per share decreased by 23.31% to ¥0.125 from ¥0.163 in the same period last year[3] - The company reported a basic and diluted earnings per share of CNY 0.125, compared to CNY 0.163 in Q1 2021[20] - The weighted average return on equity fell to 5.18%, down 3.51% from 8.69% in the previous year[3] Operating Costs and Subsidies - The company experienced a 13.66% reduction in operating costs, which amounted to ¥402,172,166.09 compared to ¥465,801,927.60 in the previous year[6] - Total operating costs for Q1 2022 were RMB 453,050,530.40, down 12.0% from RMB 514,947,064.30 year-on-year[15] - The company reported a significant increase in government subsidies, totaling ¥660,725.34, up 51.27% from ¥436,777.60[7] Investment Performance - The company’s investment income showed a substantial loss of ¥1,084,423.13, which is a 92.94% increase in losses compared to the previous year[7] - The company reported a net investment loss of RMB 1,084,423.13 in Q1 2022, compared to a loss of RMB 562,047.23 in the previous year[15] Other Information - The company did not report any new product launches or significant market expansion strategies during this quarter[22] - The company received tax refunds amounting to CNY 30.02 million, an increase from CNY 17.83 million in the previous year[20]
信隆健康(002105) - 2022 Q1 - 季度财报
2022-04-28 16:00
Financial Performance - The company's revenue for Q1 2022 was CNY 511,351,040.77, a decrease of 12.67% compared to CNY 585,539,472.88 in the same period last year[3] - Net profit attributable to shareholders was CNY 45,395,423.02, down 23.57% from CNY 59,397,700.22 year-on-year[3] - The basic earnings per share decreased by 23.31% to CNY 0.125 from CNY 0.163 in the same period last year[3] - The total comprehensive income for the period was CNY 52,007,488.29, compared to CNY 65,337,683.13 in the previous year, reflecting a decline of 20.5%[17] - The operating profit for Q1 2022 was CNY 57,840,592.69, down from CNY 70,429,974.32 in Q1 2021, representing a decline of 18.3%[17] Cash Flow and Liquidity - The net cash flow from operating activities improved significantly to CNY 15,248,893.03, compared to a negative cash flow of CNY -15,971,124.05 in the previous year, marking a 195.48% increase[3] - Cash and cash equivalents at the end of Q1 2022 were CNY 458,910,565.65, slightly down from CNY 459,199,753.69 at the beginning of the year[12] - Cash and cash equivalents at the end of the period amounted to CNY 458,910,565.65, a decrease from CNY 328,185,548.88 in the previous year[21] - The cash flow from operating activities showed a net inflow of CNY 15,248,893.03, recovering from a net outflow of CNY 15,971,124.05 in the same period last year[21] - The cash flow from investing activities showed a net outflow of CNY 14,125,948.38, improving from a net outflow of CNY 16,617,126.12 in the previous year[21] Assets and Liabilities - Total assets decreased by 5.67% to CNY 2,153,063,155.26 from CNY 2,282,516,393.71 at the end of the previous year[3] - Total liabilities decreased to CNY 1,157,427,705.21 from CNY 1,338,888,575.65, indicating a reduction of 13.5%[14] - Accounts receivable decreased to CNY 562,278,462.67 from CNY 636,496,632.73, a decline of 11.6%[13] - Inventory levels decreased to CNY 390,997,894.87 from CNY 435,013,849.64, reflecting a reduction of 10.1%[13] Shareholder Equity - The company's equity attributable to shareholders increased by 5.33% to CNY 898,415,685.89 from CNY 852,946,415.37 at the end of the previous year[3] - The weighted average return on equity fell to 5.18%, down 3.51% from 8.69% in the previous year[3] Government Support and Investment - The company reported a significant increase in government subsidies, totaling CNY 660,725.34, up 51.27% from CNY 436,777.60 in the previous year[7] - The company experienced a 92.94% increase in investment losses, reporting a loss of CNY -1,084,423.13 compared to CNY -562,047.23 in the previous year[7] Other Financial Metrics - The company reported a financial expense of CNY 6,752,926.59, which increased from CNY 4,190,943.25 in the previous year[16] - The company incurred a loss of CNY 36,219.89 from asset disposal, compared to a loss of CNY 14,514.63 in the previous year[17] - The company received CNY 30,015,998.80 in tax refunds, an increase from CNY 17,826,514.07 in the previous year[20] Operational Performance - Total operating revenue for Q1 2022 was CNY 511,351,040.77, a decrease of 12.6% compared to CNY 585,539,472.88 in the same period last year[16] - Total operating costs for Q1 2022 were CNY 453,050,530.40, down 12.0% from CNY 514,947,064.30 year-on-year[16] Product Development and Strategy - The company has not disclosed any new product developments or market expansion strategies in the current report[11]
信隆健康(002105) - 2021 Q4 - 年度财报
2022-04-22 16:00
Financial Performance - The company's operating revenue for 2021 was CNY 2,634,187,767.13, representing a 41.07% increase compared to CNY 1,867,328,488.38 in 2020[19]. - The net profit attributable to shareholders for 2021 was CNY 272,525,892.20, a 64.99% increase from CNY 165,176,203.92 in 2020[19]. - The net profit after deducting non-recurring gains and losses was CNY 246,679,804.45, up 84.95% from CNY 133,376,158.01 in 2020[19]. - The basic earnings per share for 2021 was CNY 0.7480, a 65.85% increase from CNY 0.4510 in 2020[19]. - The total assets at the end of 2021 were CNY 2,282,516,393.71, a 24.40% increase from CNY 1,834,878,332.28 at the end of 2020[19]. - The weighted average return on equity for 2021 was 36.08%, an increase of 9.36% compared to 26.72% in 2020[19]. - The net cash flow from operating activities for 2021 was CNY 225,894,732.12, a decrease of 8.06% from CNY 245,710,000.64 in 2020[19]. - The company's total revenue for the year was approximately ¥2.61 billion, with a quarterly breakdown of ¥585.54 million, ¥684.72 million, ¥642.19 million, and ¥721.73 million respectively[23]. - The net profit attributable to shareholders for the year was approximately ¥272.5 million, with quarterly figures of ¥59.40 million, ¥65.70 million, ¥77.61 million, and ¥69.81 million[23]. - The company reported a total of ¥25.85 million in non-recurring gains for the year, with significant contributions from the reversal of previously accrued legal fees[25]. - The company reported a total revenue of 1.2 billion in 2021, representing a year-over-year growth of 15%[176]. Market Trends - The global electric bicycle market is projected to reach 40 million units in sales and approximately $20 billion in revenue by 2023, with expectations to exceed $120 billion by 2030[35]. - In the U.S. market, bicycle imports reached $1.96 billion in 2021, a 40% increase year-over-year, with electric bicycle imports growing by 70% to 790,000 units[35]. - The European market saw over 22 million bicycles sold in 2021, with electric bicycles accounting for over 4.5 million units and generating sales of €10.6 billion[36]. - The domestic bicycle industry reported a production increase of 9.7% in traditional bicycles and 19.5% in electric bicycles during the first eight months of 2021[36]. - In 2021, the domestic two-wheeled electric vehicle sales reached 49.75 million units, a year-on-year increase of 4.5% compared to 47.6 million units in 2020[38]. - The electric scooter market is projected to grow at a compound annual growth rate (CAGR) of 7.6%, with an estimated increase of 30.5 million units annually, primarily driven by demand in Europe and North America[46]. - The electric scooter market is expected to face challenges due to insufficient infrastructure in major cities, but government initiatives are promoting the use of micro-mobility options[40]. - The pandemic has shifted consumer preferences towards electric scooters, with a notable increase in first-time users in North America, doubling the proportion of new users[41]. - The electric bicycle market is projected to grow significantly, with an expected increase in sales from 3 million units in 2019 to 17 million units by 2030, driven by health trends and government investments in cycling infrastructure[97]. Company Strategy and Operations - The company plans to distribute a cash dividend of CNY 2.50 per 10 shares, based on a total of 364,498,900 shares[5]. - The company has not reported any changes in its major business operations since its listing[18]. - The company does not have any significant uncertainties regarding its ability to continue as a going concern[20]. - The company aims to enhance its global market share in bicycle components while developing its own brand products to increase revenue from fitness and rehabilitation equipment[110]. - The company plans to strengthen its brand image and product quality through strategic alliances with international brands like IBD[111]. - The company is preparing to establish a European warehouse and office to shorten the supply chain and meet European customer demands[114]. - The company is focusing on expanding its electric scooter and sports equipment business, targeting major global markets[115][118]. - The company intends to participate in key exhibitions, including the Shanghai Bicycle Show and Eurobike, to explore market demands and opportunities[116]. - The company is committed to continuous product development to meet new market demands, particularly in the electric scooter segment[118]. Financial Management and Governance - The company has established a governance structure that includes a general meeting of shareholders, a board of directors, and a supervisory board, ensuring effective operational management and rapid response to business needs[141]. - The board of directors consists of 11 members, including 4 independent directors, meeting the legal requirements for board composition[145]. - The company has improved its internal control system and governance awareness among management, leading to enhanced operational transparency and compliance with regulatory requirements[142]. - The company maintains complete independence from its controlling shareholder in terms of business operations, personnel, assets, and finances, with no non-operational related transactions[144]. - The company has established independent systems for personnel management, attendance, compensation, and appointments[153]. - The company has a well-defined organizational structure with independent operational management, ensuring no interference from major shareholders in its normal business activities[154]. - The company has implemented a sales collection cycle management method to enhance its market-facing capabilities[155]. - The company has a mature development stage and plans to maintain a minimum cash dividend ratio of 40% during profit distribution[200]. Employee and Management Information - The company reported a total of 35,900 employees as of the end of the reporting period[159]. - The total number of employees at the end of the reporting period was 2,948, including 2,198 at the parent company and 750 at major subsidiaries[192]. - The company has established a comprehensive training program for employees at various levels to enhance skills and management efficiency[194]. - The company maintains a strict performance evaluation and incentive mechanism to attract and retain talent[195]. - The total remuneration for directors, supervisors, and senior management in 2021 amounted to CNY 1,354.3 million[180]. - The chairman, Liao Xuejin, received a total remuneration of CNY 393.15 million[181]. - The general manager, Liao Xuehu, received a total remuneration of CNY 455.39 million[181]. - The company’s independent directors expressed that the remuneration for 2021 was reasonable and aligned with performance[179]. Legal and Compliance Matters - The company has resolved one of the two lawsuits in the U.S. and aims to reach a settlement for the second case[133]. - The company is monitoring the impact of ongoing legal matters on its financial performance, asserting that they will not affect overall results[135]. - The company has scheduled production orders up to the third quarter of 2022, indicating potential for further order increases[134]. - The company has completed two rounds of price adjustments for raw materials by August 2021, with a third round currently in progress due to rising raw material costs[137].
信隆健康(002105) - 关于参加2021深圳辖区“沟通传递价值,交流创造良好生态”公司投资者网上集体接待日活动的公告
2021-11-25 08:28
证券代码:002105 证券简称:信隆健康 公告编号: 2021-040 深圳信隆健康产业发展股份有限公司 关于参加 2021 深圳辖区"沟通传递价值,交流创造良好生态" 上市公司投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没有虚假记载、 误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流工作, 深圳信隆健康产业发展股份有限公司(以 下简称"公司")将参加由深圳上市公司协会、深圳市全景网络有限公司共同举办的"沟 通传递价值,交流创造良好生态" ——2021深圳辖区上市公司投资者网上集体接待日 活动,现将有关事项公告如下: 本次集体接待日活动将在深圳市全景网络有限公司提供的网上平台,采取网络远程 的方式举行,投资者可以登录"全景·路演天下"网站(http://rs.p5w.net/)或关注微 信公众号:全景财经,参与公司本次投资者集体接待日活动,活动时间为2021年11月30 日14:00至17:00。 届时公司的 董事会秘书陈丽秋、财务总监邱东华、财务本部协理周杰 将通过 网络文字交流形式与投资者进行沟通。 欢迎广大投资者积极参与。 特此公告。 深圳信隆健康产 ...
信隆健康(002105) - 2021 Q3 - 季度财报
2021-10-22 16:00
Financial Performance - The company's revenue for Q3 2021 was CNY 642,194,086.80, representing a slight increase of 0.01% year-over-year, while the year-to-date revenue reached CNY 1,912,457,854.82, up 44.14% compared to the same period last year[3]. - The net profit attributable to shareholders for Q3 2021 was CNY 77,612,132.80, an increase of 15.22% year-over-year, with a year-to-date net profit of CNY 202,714,366.86, reflecting a significant increase of 79.73%[3]. - The basic earnings per share for Q3 2021 was CNY 0.213, up 15.14% year-over-year, while the diluted earnings per share also stood at CNY 0.213[3]. - Total operating revenue for Q3 2021 reached CNY 1,912,457,854.82, a significant increase of 44% compared to CNY 1,326,787,676.22 in the same period last year[19]. - Operating profit for the period was CNY 244,847,527.01, up from CNY 145,518,249.21, reflecting a growth of 68% year-over-year[19]. - Net profit attributable to the parent company was CNY 202,714,366.86, compared to CNY 112,790,015.98 in the previous year, marking an increase of 79.7%[20]. Assets and Liabilities - The company's total assets as of the end of Q3 2021 were CNY 2,183,508,626.14, which is a 19.00% increase from the end of the previous year[3]. - The total equity attributable to shareholders increased by 20.05% to CNY 785,240,130.59 compared to the end of the previous year[4]. - Total liabilities rose to CNY 1,312,843,300.37, compared to CNY 1,123,520,497.01, indicating an increase of 16.8%[17]. - The company's total assets increased to CNY 2,183,508,626.14, up from CNY 1,834,878,332.28, representing a growth of 19%[17]. Cash Flow - Cash flow from operating activities for the year-to-date period was CNY 110,158,422.51, down 37.67% compared to the previous year[3]. - Operating cash inflow for the period reached CNY 1,986,251,278.68, an increase from CNY 1,437,679,886.97 in the previous period, representing a growth of approximately 38.3%[22]. - Net cash flow from operating activities was CNY 110,158,422.51, down from CNY 176,736,950.25 in the previous period, indicating a decline of about 37.5%[23]. - Cash outflow from investing activities was CNY 90,780,476.35, compared to CNY 35,660,725.31 in the previous period, showing an increase of approximately 154.5%[24]. - Net cash flow from financing activities was -CNY 6,005,841.26, an improvement from -CNY 85,528,874.75 in the previous period, indicating a reduction in cash outflow by about 92.9%[24]. - The total cash and cash equivalents at the end of the period amounted to CNY 393,663,904.91, up from CNY 347,162,806.77 in the previous period, reflecting an increase of approximately 13.4%[24]. Research and Development - The company's research and development expenses increased significantly by 119.34% year-over-year, amounting to CNY 56,134,230.16 for the year-to-date period[9]. - Research and development expenses for the quarter were CNY 56,134,230.16, which is a 119% increase from CNY 25,592,887.19 in the same quarter last year[19]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 20,866[11]. - The largest shareholder, Litian Development Co., Ltd., holds 41.93% of the shares, totaling 154,522,500 shares[11]. Inventory and Receivables - Accounts receivable rose by 39.77% to CNY 657,457,562.33, attributed to a substantial increase in revenue during the reporting period[8]. - Inventory increased by 34.78% to CNY 402,892,878.45, driven by a rise in orders and a significant increase in raw material prices[8]. - Accounts receivable increased to ¥657,457,562.33 from ¥470,397,763.18 year-over-year[15]. Other Financial Information - The company received CNY 57,665,628.34 in tax refunds, compared to CNY 43,127,381.62 in the previous period, marking an increase of about 33.8%[23]. - Cash received from investment income was CNY 855,455.82, down from CNY 5,099,713.63 in the previous period, representing a decline of approximately 83.2%[24]. - The company paid CNY 90,602,578.96 in dividends and interest, compared to CNY 57,376,398.78 in the previous period, an increase of approximately 57.8%[24].
信隆健康(002105) - 2021 Q2 - 季度财报
2021-08-20 16:00
Financial Performance - The company's operating revenue for the first half of 2021 was CNY 1,270,263,768.02, representing an increase of 85.54% compared to CNY 684,634,974.36 in the same period last year[21]. - The net profit attributable to shareholders of the listed company reached CNY 125,102,234.06, a significant increase of 175.38% from CNY 45,428,826.59 year-on-year[21]. - The net profit after deducting non-recurring gains and losses was CNY 115,368,662.39, up 220.96% from CNY 35,944,956.46 in the previous year[21]. - The basic earnings per share increased to CNY 0.343, reflecting a growth of 178.86% compared to CNY 0.123 in the same period last year[21]. - The total revenue for the reporting period reached ¥1,270,263,768.02, an increase of 85.54% compared to ¥684,634,974.36 in the previous year[56]. - The total profit for the first half of 2021 was CNY 163,175,360.26, compared to CNY 60,835,379.51 in the same period of 2020, marking an increase of 168.5%[151]. - The company reported a total comprehensive income of CNY 139,794,830.20 for the first half of 2021, compared to CNY 50,294,399.34 in the same period of 2020, an increase of 177.5%[151]. Assets and Liabilities - The total assets of the company at the end of the reporting period were CNY 2,159,936,617.37, an increase of 17.72% from CNY 1,834,878,332.28 at the end of the previous year[21]. - The net assets attributable to shareholders of the listed company were CNY 706,166,782.43, up 7.96% from CNY 654,098,080.95 at the end of the previous year[21]. - The company's asset-liability ratio at the end of the reporting period was 63.75%, indicating potential financial risk as borrowing increases with business expansion[80]. - Total liabilities increased to CNY 1,377,010,115.22 as of June 30, 2021, from CNY 1,123,520,497.01 at the end of 2020, representing a growth of approximately 23%[143]. Cash Flow - The net cash flow from operating activities was CNY 12,396,038.70, a decrease of 87.00% compared to CNY 95,353,824.19 in the same period last year[21]. - The cash flow from operating activities for the first half of 2021 was CNY 1,187,160,037.12, compared to CNY 807,764,460.84 in the first half of 2020, indicating a strong cash generation capability[157]. - Cash outflow for purchasing goods and services rose to ¥967,310,248.89, compared to ¥554,283,272.91 in the first half of 2020, indicating a 74% increase[158]. Market and Industry Trends - The demand for electric bicycles (E-Bikes) in the European market is expected to exceed 5 million units in 2021, with projections to surpass 6.5 million units by 2025[34]. - The global electric scooter market is projected to reach between $300 billion and $500 billion within the next 10 years, driven by increasing consumer acceptance and legislative support[39]. - The overall shared bicycle market has seen a significant reduction in new deployments, with an estimated decrease of about 70% in 2021[37]. - The domestic bicycle market has seen a decline in sales due to the pandemic, with major clients experiencing inventory adjustments of approximately 30-40%[36]. Research and Development - The company's R&D investment increased by 222.42% to ¥33,392,546.46, reflecting a commitment to innovation and new product development[58]. - Research and development expenses for the first half of 2021 were CNY 33,392,546.46, significantly higher than CNY 10,356,856.65 in the same period of 2020, indicating a focus on innovation[148]. Environmental and Social Responsibility - Environmental protection measures are in compliance with regulations, and pollution control facilities are operating normally at Tianjin Xinlong[89]. - The company employed 20 disabled individuals and 89 people from impoverished areas, distributing a total salary of RMB 3,598,463 during the reporting period from January to June 2021[93]. - The company is currently conducting underground soil remediation work at the original CP workshop, expected to be completed by October 2021[92]. Governance and Compliance - The company has established a multi-tier governance structure, including a board of directors and various specialized committees[179]. - The company's financial reports comply with the requirements of the enterprise accounting standards, reflecting its financial status and operating results accurately[184]. - The semi-annual financial report for the company was not audited[99]. Strategic Initiatives - The company aims to enhance its market share through continuous investment in new technologies and products, with a focus on high-tech transformation of traditional industries[55]. - The company plans to expand its outdoor sports product orders significantly, driven by increased demand post-pandemic[62].
信隆健康(002105) - 2021 Q1 - 季度财报
2021-04-27 16:00
Financial Performance - The company's revenue for Q1 2021 reached ¥585,539,472.88, representing a 149.42% increase compared to ¥234,761,032.32 in the same period last year[8] - Net profit attributable to shareholders was ¥59,397,700.22, a significant turnaround from a loss of ¥6,497,831.29, marking an increase of 1,014.12%[8] - The net profit after deducting non-recurring gains and losses was ¥55,160,678.45, compared to a loss of ¥10,135,373.88, reflecting a 644.24% improvement[8] - Basic earnings per share rose to ¥0.163 from a loss of ¥0.018, an increase of 1,005.56%[8] - The weighted average return on equity improved to 8.69%, up 9.88 percentage points from -1.19%[8] - Net profit for Q1 2021 was ¥65.25 million, representing a remarkable increase of 730.43% from a net loss of ¥10.35 million in Q1 2020[16] - Operating profit for Q1 2021 reached CNY 70,429,974.32, a significant increase from a loss of CNY 13,844,985.29 in the same period last year[41] - The total comprehensive income for Q1 2021 was CNY 65,337,683.13, compared to a loss of CNY 10,075,610.10 in the previous year[42] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,903,756,096.17, a 3.75% increase from ¥1,834,878,332.28 at the end of the previous year[8] - The total liabilities rose slightly to CNY 1,127,060,577.77 from CNY 1,123,520,497.01, showing a marginal increase of about 0.2%[33] - The owner's equity increased to CNY 776,695,518.40 from CNY 711,357,835.27, representing an increase of approximately 9.2%[34] - The total current liabilities amounted to CNY 990,619,766.70, compared to CNY 981,497,937.57 in the previous period, indicating an increase of approximately 0.1%[33] Cash Flow - The net cash flow from operating activities was negative at -¥15,971,124.05, a decline of 125.30% compared to ¥63,131,847.87 in the same period last year[8] - Operating cash inflow for the current period was CNY 592,070,605.19, an increase from CNY 475,061,088.23 in the previous period, representing a growth of approximately 24.7%[49] - Cash outflow from operating activities totaled CNY 608,041,729.24, compared to CNY 411,929,240.36 in the prior period, indicating an increase of about 47.5%[49] - Cash inflow from investment activities was CNY 1,027,342.94, up from CNY 553,253.37, marking an increase of approximately 85.8%[49] - Cash outflow from investment activities rose to CNY 17,644,469.06 from CNY 6,070,712.95, reflecting an increase of about 190.5%[49] - Cash inflow from financing activities was CNY 132,117,249.51, down from CNY 240,874,241.97, a decrease of approximately 45.0%[50] - The net cash flow from financing activities was negative CNY 18,861,792.14, a decline from a positive CNY 7,610,421.50 in the previous period[50] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 21,628[11] - Net assets attributable to shareholders increased by 9.09% to ¥713,532,470.06 from ¥654,098,080.95[8] Research and Development - Research and development expenses surged by 218.98% to ¥13.64 million, up from ¥4.28 million in the same period last year, indicating increased investment in innovation[15] - Research and development expenses increased to CNY 13,639,220.44 in Q1 2021, up from CNY 4,275,879.16 in the same period last year, reflecting a focus on innovation[41] Inventory and Receivables - Accounts receivable rose by 20.86% to ¥568.52 million, reflecting a substantial increase in revenue and corresponding receivables[15] - The company’s inventory increased by 9.17% to ¥326.33 million, indicating a buildup of stock in anticipation of future sales[15] - Accounts receivable increased to ¥568,520,994.14 as of March 31, 2021, compared to ¥470,397,763.18 at the end of 2020, reflecting improved sales performance[31] - Inventory levels rose to ¥326,330,364.85 as of March 31, 2021, up from ¥298,915,970.20 at the end of 2020, indicating increased production activity[31] Tax and Expenses - The company reported a 97.78% increase in income tax expenses to ¥17.54 million, driven by a substantial rise in profitability[15] - The company incurred tax expenses of CNY 9,750,231.06 in Q1 2021, compared to CNY 674,183.23 in the same period last year[41] Operational Insights - The company reported government subsidies of ¥436,777.60 during the period[9] - The company reported that the order production for Q4 2020 was fully booked, indicating strong demand[26] - The company anticipates that the Q1 2021 orders are expected to be robust, maintaining full production capacity[27] - The company is closely monitoring government policies related to carbon neutrality and plans to develop corresponding strategies[27] - The company faced challenges in 2019 due to rising operational costs and tariffs, which significantly impacted its performance that year[27]